13F HOLDINGS REPORT
Decheng Capital LLC
Quarter ended Q1 2025 · Filed May 8, 2025 · Accession 0001104659-25-045686
Total Value
$356.5M
Positions
27
Other Managers
0
Confidential Omitted
No
Holdings (27)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | CG ONCOLOGY INC | CGON | 6,371,669 | $156.0M | 43.77% |
| 2 | Nuvation Bio Inc. | NUVB | 25,954,439 | $45.7M | 12.81% |
| 3 | AARDVARK THERAPEUTICS INC | AARD | 3,917,299 | $29.4M | 8.25% |
| 4 | Upstream Bio Inc. | UPB | 3,285,293 | $20.1M | 5.64% |
| 5 | NEWAMSTERDAM PHARMA CO NV | NAMSW | 770,000 | $15.8M | 4.42% |
| 6 | KRYSTAL BIOTECH INC | KRYS | 65,000 | $11.7M | 3.29% |
| 7 | REVOLUTION MEDICINES INC(NSM) | RVMDW | 226,000 | $8.0M | 2.24% |
| 8 | MERUS NV | N5749R100 | 189,098 | $8.0M | 2.23% |
| 9 | BeyondSpring Inc. | BYSI | 4,882,651 | $7.0M | 1.96% |
| 10 | MOONLAKE IMMUNOTHERAPEUTICS | MLTX | 171,600 | $6.7M | 1.88% |
| 11 | Lyell Immunopharma, Inc. | LYEL | 11,909,341 | $6.4M | 1.80% |
| 12 | Arcus Biosciences, Inc | RCUS | 808,789 | $6.3M | 1.78% |
| 13 | Aclaris Therapeutics, Inc. | ACRS | 4,041,736 | $6.2M | 1.73% |
| 14 | CRINETICS PHARMACEUTICALS IN | CRNX | 177,958 | $6.0M | 1.67% |
| 15 | CYTOKINETICS INC | CYTK | 100,000 | $4.0M | 1.13% |
| 16 | LEGEND BIOTECH CORP-ADR | LEGN | 100,000 | $3.4M | 0.95% |
| 17 | ARCELLX INC | ACLX | 50,000 | $3.3M | 0.92% |
| 18 | Zentalis Pharmaceuticals Inc. | ZNTL | 2,019,762 | $3.2M | 0.90% |
| 19 | Aura Biosciences, Inc. | AURA | 515,555 | $3.0M | 0.85% |
| 20 | Biontech SE-ADR | BNTX | 20,000 | $1.8M | 0.51% |
| 21 | Equillium Inc. | EQ | 4,447,308 | $1.7M | 0.49% |
| 22 | 4D MOLECULAR THERAPEUTICS IN | FDMT | 335,515 | $1.1M | 0.30% |
| 23 | Illumnia, Inc. | ILMN | 11,749 | $932,166 | 0.26% |
| 24 | Pyxis Oncology, Inc (formerly Apexigen) | PYXS | 326,810 | $320,241 | 0.09% |
| 25 | GRAIL INC | GRAL | 9,684 | $247,329 | 0.07% |
| 26 | VERA THERAPEUTICS INC | VERA | 4,495 | $107,970 | 0.03% |
| 27 | Nuvation Bio Inc. | NUVB | 646,057 | $43,990 | 0.01% |